Valuation: Fennec Pharmaceuticals Inc.

Market Cap 384M 344M 316M 287M 536M 36.46B 546M 3.77B 1.51B 19.18B 1.44B 1.41B 60.48B P/E 2026 *
36.5x
P/E 2027 * 11.1x
Enterprise Value 384M 344M 316M 287M 536M 36.46B 546M 3.77B 1.51B 19.18B 1.44B 1.41B 60.48B EV / Sales 2026 *
5.29x
EV / Sales 2027 * 3.72x
Free-Float
78.7%
Yield 2026 *
-
Yield 2027 * -
1 day-6.76%
1 week+2.68%
Current month-2.82%
1 month-2.82%
3 months+4.44%
6 months+59.48%
Current year+34.42%
1 week 9.98
Extreme 9.98
11.25
1 month 9.87
Extreme 9.87
11.25
Current year 5.65
Extreme 5.65
13.25
1 year 5.65
Extreme 5.65
13.25
3 years 3.96
Extreme 3.96
13.25
5 years 3.82
Extreme 3.8219
13.25
10 years 1.64
Extreme 1.6439
14.99
Manager TitleAgeSince
Chief Executive Officer 64 16/08/2024
Director of Finance/CFO 51 06/01/2010
Chief Tech/Sci/R&D Officer 51 28/10/2024
Director TitleAgeSince
Director/Board Member 72 25/08/2011
Chairman 69 09/12/2015
Director/Board Member 70 10/08/2016
Date Insider Type Main position Quantity % Market Cap. Importance
10/12/26 A Free

Executive/Senior Manager

2,326 0.0066%
10/12/26 A Free

Chief Executive Officer

2,224 0.0063%
10/12/26 A Free

Chief Financial Officer

3,846 0.0110%
Change 5-day change 1-year change 3-year change Capi.($)
-6.76%+2.68%+24.25%+50.44% 384M
+3.10%+11.01%+67.40%+149.90% 1,224B
-0.62%+3.83%+44.88%+86.29% 662B
+1.22%+2.84%+28.73%+107.03% 514B
+0.42%+3.20%+54.15%+67.18% 388B
+2.31%+3.04%+73.48%+45.77% 361B
+1.12%+4.52%+35.30%+58.08% 302B
+6.96%+8.86%+11.27%+36.62% 271B
+1.21%+6.25%+59.83%+77.33% 249B
+3.08%+9.78%+44.63%+120.26% 205B
Average +1.24%+2.94%+44.39%+79.89% 417.72B
Weighted average by Cap. +1.93%+3.04%+50.83%+98.07%

Financials

2026 *2027 *
Net sales 72.56M 64.99M 59.78M 54.16M 101M 6.89B 103M 713M 286M 3.62B 272M 267M 11.43B 103M 92.35M 84.94M 76.97M 144M 9.79B 147M 1.01B 407M 5.15B 387M 379M 16.24B
Net income 10.48M 9.38M 8.63M 7.82M 14.62M 995M 14.89M 103M 41.33M 523M 39.33M 38.49M 1.65B 35.13M 31.46M 28.94M 26.22M 49.01M 3.34B 49.93M 345M 139M 1.75B 132M 129M 5.53B
Net Debt - -
Projected Income Statement - Annual - Fennec Pharmaceuticals Inc.
Logo Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate, PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is an approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase III clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. It has established Fennec HEARS, a single source program designed to connect PEDMARK patients.
Employees
35
Date Price Change Volume
30/10/26 $10.35 -5.48% 123,669
29/10/26 $10.95 +0.74% 180,560
28/10/26 $10.87 +2.35% 149,545
27/10/26 $10.62 +4.63% 93,186
26/10/26 $10.15 +0.69% 115,942
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Fennec Pharmaceuticals Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
10.95USD
Average target price
17.67USD
Spread / Average Target
+61.34%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Fennec Pharmaceuticals Inc.
  1. Stock Market
  2. Stocks
  3. FENC Stock